Nature头条：GLP-1类减肥药有望治疗新病症——偏头痛

Core Viewpoint - The article discusses a clinical trial indicating that the GLP-1 receptor agonist Liraglutide may significantly reduce the frequency of migraine attacks in obese patients suffering from migraines, with a reported reduction of nearly 50% in monthly migraine occurrences [1][3][8]. Group 1: Clinical Trial Insights - The clinical trial is the first to explore the potential of GLP-1 receptor agonists in migraine suppression [3][4]. - The study involved 31 participants with chronic migraines and obesity (BMI > 30 kg/m²), all of whom had previously tried at least two preventive migraine medications without success [8]. - After 12 weeks of Liraglutide treatment, participants reported a decrease in average headache days from nearly 20 to less than 11 per month, with 15 participants experiencing at least a 50% reduction in headache frequency [8]. Group 2: Mechanism and Future Research - The research team suggests that the alleviation of migraines may not be solely due to weight loss, as participants did not experience significant weight changes during the trial, indicating that Liraglutide may act more directly on pain pathways [9]. - A hypothesis is proposed that slight increases in intracranial pressure could be a potential mechanism for migraine onset, with GLP-1 drugs shown to reduce intracranial pressure in animal studies [10]. - Plans for a larger randomized controlled trial are underway to validate the hypothesis, which will also measure changes in intracranial pressure in relation to headache relief [11].